Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments (2016 - 2023)

Cartesian Therapeutics (RNAC) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $28.3 million in Q1 2023.

• On a quarterly basis, Change in Acquisitions & Divestments rose 182.54% year-over-year to $28.3 million in Q1 2023; TTM through Dec 2023 was $28.3 million, a 43.42% increase from a year earlier, with the FY2023 full-year figure at $28.3 million, up 43.42% from the prior year.
• Change in Acquisitions & Divestments for Q1 2023 stood at $28.3 million, up from $5.7 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for RNAC reached as high as $28.3 million in Q1 2023 and fell as low as -$14.4 million in Q4 2019.
• Historically, Change in Acquisitions & Divestments has averaged $6.6 million across 4 years, with a median of $6.0 million in 2021.
• Across the five-year window, Change in Acquisitions & Divestments sank 134.47% in 2019 and soared 182.54% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at -$14.4 million in 2019, then soared by 169.65% to $10.0 million in 2021, then tumbled by 43.0% to $5.7 million in 2022, then soared by 395.68% to $28.3 million in 2023.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $28.3 million in Q1 2023, $5.7 million in Q4 2022, and $4.0 million in Q3 2022.